This cohort was subdivided into two groups: multiple tumor patients with a combination of PC/PGL/HNPGL + RCC (n = 12 probands; group A) and familial non-VHL RAPTAS cases with RCC or PC/PGL/HNPGL and an FDR with the alternative tumor type (n = 21 patients, 10 probands; group B). This evidence concerns the gene VHL and renal cell carcinoma.